A drug molecule developed by Artificial Intelligence (AI) will be used in human trials in the world for the first time for machine learning in medicine. It was developed by a British startup company called Exscientia and a Japanese Pharmaceutical firm called Sumitomo Dainippon Pharma.
Drug developed will be used to treat patients suffering from Obsessive Compulsive Disorder (OCD). Normally drug development would take about 5 years to be sent for a trial but in this case, it took about twelve months.
Prof Andrew Hopkins, Chief Executive at Exscientia said a mile stone has been reached in drug discovery. He told the BBC that AI is used to diagnose patients and analyzing patient’s data. Molecule DSP – 1181 was actually created by using Algorithms with the use of potential compounds.
This drug will undergo phase one trials in Japan if found successful, after which it will be followed by more global tests.